In two patients with BIF5B-RET or CCDC6-RET + NSCLCs treated with selpercatinib, acquired heterogenous front solvent G810X (G810R, G810S, and G810C at different tumor sites) RET mutations were documented, which can sterically inhibit the binding of selpercatinib to RET fusions [89]. This evidence concerns the gene RET and neoplasm.